Intratumoral stromal morphometry predicts disease recurrence but not response to 5‐fluorouracil—results from the QUASAR trial of colorectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2559|72|3|391-404

ISSN： 0309-0167

Source： HISTOPATHOLOGY, Vol.72, Iss.3, 2018-02, pp. : 391-404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Alternating Regimen of Irinotecan/ 5-Fluorouracil/Folinic Acid and Oxaliplatin/ 5-Fluorouracil/Folinic Acid in Metastatic Colorectal Cancer: A Phase II Trial

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 283-289

Karger

Access to resources Recommend Favorite

A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer

By  

Oncology, Vol. 69, Iss. 1, 2005-09 ,pp. : 63-70

Karger

Access to resources Recommend Favorite

mdm2-p53 Interaction: Lack of Correlation with the Response to 5-Fluorouracil in Advanced Colorectal Cancer

By  

Oncology, Vol. 62, Iss. 3, 2002-06 ,pp. : 278-285

Karger

Access to resources Recommend Favorite

Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial

By  

Oncology Research and Treatment, Vol. 23, Iss. 5, 2000-11 ,pp. : 444-447

Karger

Access to resources Recommend Favorite

Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 134-139

Karger

Access to resources Recommend Favorite